Namrata Shah
Infectious Disease · Greenbelt, MDNPI 1275848764
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Merck at 48.6% of the total. 2025 is the largest year on record at $4,318, more than ten times the $416 reported in 2022.
Across 72 payments — averaging $116.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4K
- Viiv Healthcare Company$2K
- Gilead$2K
- Novo Nordisk$73
- Theratechnologies Inc.$67
- Janssen Scientific Affairs, LLC$24
Across 184 payments — averaging $11,459 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Theratechnologies Inc.$831K
- Merck$520K
- Gilead$406K
- Viiv Healthcare Company$228K
- GSK$63K
- Janssen Research & Development, LLC$60K
What the payments were for
- Travel & lodging$4,73756%
- Food & beverage$3,62143%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 23 | $4,076 |
| Viiv Healthcare Company | 21 | $2,439 |
| Gilead | 23 | $1,711 |
| Novo Nordisk | 2 | $73 |
| Theratechnologies Inc. | 2 | $67 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,390 in reported general payments places this provider in the 85th percentile of 289 infectious disease providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 163 | $673,786 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 31 | $184,208 |
| RukobiaFostemsavir Tromethamine | 13 | $128,104 |
| JulucaDolutegravir/Rilpivirine | 33 | $112,208 |
| TivicayDolutegravir Sodium | 43 | $108,649 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 18 | $71,665 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 15 | $57,385 |
| TrulicityDulaglutide | 30 | $36,033 |
| Darunavir | 18 | $29,434 |
| MounjaroTirzepatide | 18 | $25,974 |
| PifeltroDoravirine | 15 | $25,568 |
| JardianceEmpagliflozin | 19 | $24,056 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,392 |
| Ritonavir | 18 | $3,624 |
| Atazanavir Sulfate | 11 | $2,692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $1,711 | $745,451181 claims |
| Viiv Healthcare CompanyRukobia, Juluca, Tivicay, Triumeq | $2,439 | $406,346104 claims |
| MerckPifeltro | $4,076 | $25,56815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 289 infectious disease providers in Maryland.
Other infectious disease in Greenbelt
- Robert RedfieldBaltimore$779K
- Luciana BorioBaltimore$671K
- Philip KrausePotomac$659K
- Mark SulkowskiBaltimore$240K
- Jonathan ZenilmanBaltimore$202K
- Phuong TrinhSilver Spring$196K
- Robert EdelmanBaltimore$125K
- Kjell WibergBaltimore$113K
- Wellington SunRockville$85K
- Michael PolisBethesda$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.